In healthy people, (the meningococcus) is a typical component of the nasopharyngeal microbiome, but in those who are susceptible, it can cause septicemia and meningitis. This section gives a general overview of the meningococcus types and the sickness induced by Evaluate genes for phase-changeable adhesions, virulence factors, and effective colonization of the human host. In our final section, we summarize the evolution of meningococcal vaccines and their current state while emphasizing the value of ongoing molecular research into the pathogen's epidemiology and structural analysis of its antigens. IMD is a major global source of morbidity and mortality and a public health concern. IMD can manifest as an epidemic with breakouts or as an endemic illness with sporadic instances. There are 13 serogroups of Neisseria meningitis strains, however, only five (A, B, C, W-135, and Y) account for the majority of IMD globally. IMD poses a risk to people of all ages, although young children and teenagers are especially at risk. Meningitis and septicemia are the two clinical symptoms of IMD that occur most frequently, while both clinical presentations can occasionally exist. Age might affect the clinical pattern; in early childhood, the clinical manifestations could be more subtle, and the diagnosis may be trickier than in older kids or teenagers. In 4.3-11.2% of instances, there are sequelae, and death occurs in 6-10% of cases. Although vaccination remains the most effective method of preventing meningococcal disease, it is crucial to identify children with meningococcal infection as soon as possible to begin systemic antibiotic therapy. The prevalence of the disease has decreased as a result of the recent introduction of various meningococcal vaccinations on a global scale. Increasing meningococcal disease vaccination rates, keeping an eye on IMD, and creating a special vaccine that can protect against all of the major meningococcal strains should be the priorities for the upcoming few years.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10704056 | PMC |
http://dx.doi.org/10.7759/cureus.48509 | DOI Listing |
Lancet Digit Health
December 2024
Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address:
Microbiology reference laboratories perform a crucial role within public health systems. This role was especially evident during the COVID-19 pandemic. In this Viewpoint, we emphasise the importance of microbiology reference laboratories and highlight the types of digital data and expertise they provide, which benefit national and international public health.
View Article and Find Full Text PDFBull Cancer
December 2024
Service d'oncologie hématologie pédiatrique, hôpital universitaire Armand-Trousseau (AP-HP), Paris, France; Centre d'investigations cliniques, hôpital Cochin, Paris, France. Electronic address:
Children and adolescents who are being treated or have been treated for acute leukemia have a secondary immunodeficiency linked to chemotherapy, resulting in an increased risk of infections. Some of which can be prevented by vaccination but its effectiveness is not optimal during chemotherapy. Upon cessation of chemotherapy, the time required for immune reconstitution varies from three months to more than a year, depending on lymphocyte subpopulations, the patient's age, and the intensity of the treatment received.
View Article and Find Full Text PDFChina CDC Wkly
November 2024
Hebei Provincial Center for Disease Control and Prevention Bacterial Disease Prevention and Disinfection Institute, Hebei Key Laboratory of Pathogens and Epidemiology of Infectious Diseases, Shijiazhuang City, Hebei Province, China.
What Is Already Known About This Topic?: (Nm) is a bacterial pathogen that causes meningococcal disease. Serogroups A, B, C, W, X, and Y account for the vast majority of cases. However, invasive meningococcal disease (IMD) caused by NmY is rare in China and has been reported only in Tianjin, Guangdong, Shanghai, and Hunan provinces and cities.
View Article and Find Full Text PDFCommun Dis Intell (2018)
December 2024
World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia.
In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). When compared to 2022, the number of IMD notifications in 2023 increased by 14% to 143. Laboratory confirmation of IMD occurred in 140/143 (98%) of these cases, with 64% (90/140) diagnosed by bacterial culture and 36% (50/140) by nucleic acid amplification testing.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2024
Real-World Evidence, Evidera, Waltham, MA, USA.
Invasive meningococcal disease (IMD) is a life-threatening yet vaccine-preventable disease, with vaccines approved and recommended in the United States by the Centers for Disease Control and Prevention. This study assessed complications, mortality, healthcare resource utilization (HCRU), and healthcare costs among a sample of commercially-insured individuals living in the United States who experienced IMD. We used retrospective data from large claims databases limited to individuals with IMD covered by commercial health plans between January 2010-March 2022.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!